Table 2 Baseline data: “controls”: 47 pregnant patients on unrestricted diet in pregnancy (22 singleton deliveries in Cagliari, 20 in Torino)
Case | Age (yrs) | Pre-conceptional; Referral-week | Kidney disease | sCr mg/dL (EPI-GFR mL/min) | CKD stage | PtU (g/24 h) | Pt/Alb (g/dL) | HT | Therapy at referral | BMI |
|---|---|---|---|---|---|---|---|---|---|---|
1 | 33 | 11w | IgA GN | 0.9 (84.3) | 2 | 1.1 | 6.0/2.9 | No | Pred | 20.2 |
2 | 34 | pre; 7w | SLE | 0.7 (113.4) | 1 | 1.3 | 5.8/3.5 | No | Steroids, AZA | 19.6 |
3 | 34 | pre; 6w | SLE | 0.7 (113.4) | 1 | 1.3 | 6.3/2.9 | Yes | a-MD, Pred., CyA | 20.8 |
4 | 38 | pre; 22w | Unknown | 0.8 (93.8) | 1 | 1.7 | Na | Yes | ASA, Nifedipine, a-MD | 26 |
5 | 29 | pre; 5w | IgA GN | 0.9 (86.7) | 2 | 2.1 | 6.3/3.5 | Yes | a-MD | 22.1 |
6 | 26 | pre; 8w | Diab neph | 0.4 (144.2) | 1 | 2.6 | 5.6/3.3 | No | ASA, Insulin | 23.4 |
7 | 35 | pre; 7w | SLE, LLAC | 0.5 (129.3) | 1 | 3.9 | 5.2 /2.9 | No | Pred | 20.2 |
8 | 19 | pre; 13w | SLE | 0.6 (135.6) | 1 | 4 | 5.9/3 | No | none | 18.8 |
9 | 36 | pre; 13w | FSGS | 0.9 (82.5) | 2 | 4.2 | 5.7/3.1 | Yes | ASA, a-MD | 20.3 |
10 | 41 | pre; 6w | SLE | 1 (71.9) | 2 | 5.4 | 5.5/3.6 | Yes | a-MD | 18.3 |
11 | 35 | pre; 20w | Diab neph | 1.2 (58.7) | 3 | 0.1 | Na | Yes | a-MD, Insulin | 25.6 |
12 | 39 | pre; 7w | SLE | 1.4 (47.4) | 3 | 0.3 | 6.5/3.7 | Yes | Pred., AZA | 23 |
13 | 32 | pre; 9w | SLE | 1.4 (49.8) | 3 | 0.8 | 6.7/4.5 | Yes | Pred | 21.6 |
14 | 35 | pre; 8w | IgA GN | 1.4 (50) | 3 | 1.7 | 6.8/3.3 | No | none | 24.8 |
15 | 38 | pre; 7w | Unknown | 1.6 (40.6) | 3 | 1.4 | 6.2/4.3 | No | none | 23.9 |
16 | 31 | 6w | IgA GN | 1.6 (42.6) | 3 | ++ | 7/3.3 | No | none | 32.5 |
17 | 36 | pre; 6w | GN | 1.8 (35.7) | 3 | 0.4 | 7.3/ 4 | No | none | 22.5 |
18 | 23 | pre; 13w | Unknown | 1.9 (36.6) | 3 | 2.8 | 6.1/ 3 | No | none | 30.1 |
19 | 30 | na | IgA GN | 1.4 (50) | 3 | 6.2 | na | Yes | a-MD | 21.6 |
20 | 34 | pre; 12w | SLE, LLAC | 2.2 (28.4) | 4 | 1.2 | 5.7/3.2 | Yes | a-MD, ASA, EPO | 21.4 |
21 | 28 | 7w | Unknown | 1.6 (43.9) | 3 | 1.6 | 7.4/ 4.3 | No | none | 23.7 |
22 | 33 | pre; 12w | GN | 0.5 (127.6) | 1 | 1.1 | 7/4 | No | none | 21.8 |
Summary data Cagliari | 34 (19–41) | 8 (5–22) | sCr 1.1 (0.4–2.2) GFR-EPI 65.3 (28.4–144.2) | 1.6 (0.1–6.2) | Pt 6.2 (5.2–7.4) Alb 3.3 (2.9–4.5) | 10 45.5 % | 21.95 (18.3–32.5) | |||
1 | 39 | Pre; 8 w | Interstitial | 1.6 (40) | 3 | 1.3 | 7.3 /3.7 | Yes | Felodipine, Doxazosin, Levotiroxina, ASA | 26.7 |
2 | 27 | 14 w | Reflux | 1.5 (47) | 3 | 0.3 | 6.5/3.4 | No | None | 18.0 |
3 | 34 | 20 w | Chronic PN | 1.5 (45) | 3 | 2.0 | Na | No | None | 23.3 |
4 | 23 | 13 w | IgA GN | 1.3 (56) | 3 | 0.5 | 6.4/3.1 | Yes | a-MD, ASA | 22.7 |
5 | 32 | Pre; 5 w | IgA GN | 1.2 (58) | 3 | 0.3 | 6.1/3.4 | No | Steroids, Allopurinole | 19.1 |
6 | 35 | Pre; 8 w | IgA GN | 1.3 (54) | 3 | 0.5 | 6.6/2.7 | Yes | a-MP, Niphedipine | 24.4 |
7 | 22 | 27 w | Reflux | 2.9 (22) | 4 | 0.5 | 7.3/3.4 | No | Niphedipine | 22.2 |
8 | 39 | Pre; 14 w | Chronic PN | 1.4 (47) | 3 | 0.2 | 8.1/4.0 | Yes | B-bloc, ASA | 18.4 |
9 | 31 | 20 w | Reflux | 1.3 (54) | 3 | 0.6 | 7.2/3.7 | Yes | B-bloc, Doxazosine, Niphedipine, Isosorbide | 19.5 |
10 | 25 | 33 w | Reflux | 1.3 (57) | 3 | 0.8 | 6.0/3.1 | Yes | a-MP | 19.3 |
11 | 35 | 7; w | Interstitial | 1.3 (52) | 3 | 0.6 | 6.0/3.2 | Yes | None | 25.6 |
12 | 33 | Pre; 12w | Chronic PN | 1.2 (60) | 3 | 0.1 | 6.4/3.2 | No | Clonidine, a-MP, ASA | 19.7 |
13 | 30 | 6 w | Kidney graft | 1.2 (59) | 3 | 0.2 | 7.6/3.2 | No | TAC, Pred, Pantoprazole, Allopurinolo | 20.3 |
14 | 32 | 29 w | HIV neph. | 1.43 (56) | 3 | 0.4 | 7.0/3.1 | No | Antiretroviral therapy Omeprazole | 20.0 |
15 | 36 | 6 w | Kidney graft | 1.1 (56) | 3 | 0.1 | 6.9/4.7 | No | Pred, CyA, Omeprazole, ASA | 24.7 |
16 | 38 | Pre; 8 w | single kidney | 0.8 (56) | 3 | 0.1 | 6.8/4.4 | No | Calcium carbonate | 15.6 |
17 | 27 | 5 w | SLE | 0.6 (193.6) | 1 | 1.45 | 7.09/4.37 | No | ASA, Steroids | 30.4 |
18 | 37 | 20 w | FSGS | 0.7 (81.6) | 2 | 2.33 | 6.56/3.62 | No | none | 23.6 |
19 | 26 | 12 w | IR e proteinuria | 1.1 (101.2) | 1 | 2 | 6.45/3.49 | No | ASA | 32.4 |
20 | 36 | 16 w | PNC | 0.6 (122) | 1 | 1.03 | 7.55/4.10 | No | Thyroxine | 20.2 |
21 (miscarriage) | 38 | 7 w | Chronic PN, single kidney | 1.9 (31) | 3 | 0.1 | 7.3/5.0 | No | None | 24.9) |
22 (miscarriage) | 37 | Pre; 8 w | Single kidney | 0.8 (58) | 3 | 0.1 | 7.6/4.7 | No | None | 15.6 |
23 (miscarriage) | 36 | 5 w | Kidney graft | 1.3 (53) | 3 | 0.4 | Na | No | CyA, AZA | 25.5 |
24 (miscarriage) | 37 | Pre; 5 w | single kidney | 0.9 (55) | 3 | 0.1 | na | No | Calcium carbonate, | 16.2 |
25 (miscarriage) | 30 | 9 w | Diab. Neph | 1.4 (50) | 3 | 0.2 | 6.9/4.1 | No | Insuline | 22.7 |
Summary data Torino | 34 (22–39) | 9 (5–33) | _ | sCr 1.3 (0.6–2.9) GFR-EPI 56.0 (22.0–193.6) | 3 (1–4) | 0.4 (0.1–2.33) | Pt 6.9 (6.0–8.1) Alb 3.55 (2.7–5.0) | 7 28.0 % | _ | 22.2 (15.6–32.4) |
Summary data all controls: 42 singleton | 33.5 (19–41) | 9 (5–33) | _ | sCr 1.25 (0.4–2.9) GFR-EPI 56.0 (22.0–193.6) | 3 (1–4) | 1.1 (0.1–6.2) | Pt 6.5 (5.2–8.1) Alb 3.4 (2.7–4.7) | 17 40.5 % | _ | 21.95 (15.6–32.5) |
P cases vs controls (singletons) | 0.443 | 0.154 | _ | sCr 0.716 GFR-EPI 0.680 | 0.139 Chi 2 | 0.585 | Pt 0.952 Alb 0.073 | 0.479 (Chi2) | _ | 0.237 |